Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment

Am Heart J. 2015 Jan;169(1):186-7. doi: 10.1016/j.ahj.2014.09.004. Epub 2014 Sep 19.

¹ Guys and St Thomas' NHS Trust, Department of Haematology, London, United Kingdom. Electronic address: alexander.cohen@kcl.ac.uk.
² Stanford University School of Medicine, Interventional Cardiology, Stanford, CA.
³ Brigham and Women's Hospital, Cardiovascular Division, Boston, MA.
⁴ University of Calgary, Thrombosis Research Unit, Calgary, Alberta, Canada.
⁵ Beth Israel Deaconess Medical Center, Cardiovascular Division, Boston, MA.
⁶ Duke University, Duke Clinical Research Institute, Durham, NC.
⁷ Portola Pharmaceuticals, San Francisco, California, United States of America.

No abstract available

Publication types